| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P6179 | Dimensions Publication ID | 1020698671 |
| P356 | DOI | 10.1007/S10620-016-4291-2 |
| P3181 | OpenCitations bibliographic resource ID | 3572722 |
| P932 | PMC publication ID | 5067290 |
| P698 | PubMed publication ID | 27619394 |
| P2093 | author name string | Da-Zhi Zhang | |
| Qiong-Fang Zhang | |||
| Qiu-Feng He | |||
| P2860 | cites work | Direct anti-HCV agents | Q26767329 |
| New approaches in the treatment of hepatitis C | Q26773271 | ||
| Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 | ||
| Enhancing our understanding of current therapies for hepatitis C virus (HCV) | Q28085718 | ||
| Interferon-free combination therapies for the treatment of hepatitis C: current insights | Q28087400 | ||
| Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection | Q29619800 | ||
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 | ||
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis | Q29620612 | ||
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 | ||
| Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study | Q33956796 | ||
| Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial | Q34038836 | ||
| Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects | Q34164776 | ||
| Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection | Q34386833 | ||
| Global distribution and prevalence of hepatitis C virus genotypes | Q34431175 | ||
| Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial | Q34649453 | ||
| High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study | Q36651317 | ||
| Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis | Q37035896 | ||
| Ever closer to a prophylactic vaccine for HCV. | Q37089122 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| Assessing quality of reports on randomized clinical trials in nursing journals. | Q37515243 | ||
| Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. | Q37851006 | ||
| Natural history of acute and chronic hepatitis C | Q38063990 | ||
| Effect of IL28B genotype on hepatitis B and C virus infection | Q38568999 | ||
| Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial | Q40780423 | ||
| Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. | Q41172899 | ||
| Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease | Q41222268 | ||
| Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial | Q41343312 | ||
| Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). | Q41429836 | ||
| Screening for hepatitis C. | Q41744337 | ||
| Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. | Q42205980 | ||
| Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. | Q42988738 | ||
| 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end | Q42992965 | ||
| Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q43034904 | ||
| A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C. | Q43046523 | ||
| Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals | Q43100552 | ||
| Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006 | Q64128835 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q86939378 | ||
| Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties | Q95542311 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nucleotide | Q28745 |
| heterocyclic compound | Q193430 | ||
| hydrocarbon | Q43648 | ||
| ribavirin | Q421862 | ||
| polycyclic compound | Q426145 | ||
| sofosbuvir | Q2502747 | ||
| ledipasvir | Q15409409 | ||
| RNA virus infectious disease | Q18967413 | ||
| antiviral agent | Q40207875 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 3108-3117 | |
| P577 | publication date | 2016-11-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis | |
| P478 | volume | 61 |
| Q92625996 | Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions |
| Q50587241 | Effect of Antithrombotic Therapy and Long Endoscopic Submucosal Dissection Procedure Time on Early and Delayed Postoperative Bleeding |
| Q61447399 | Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis |
| Q39262589 | Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials |
Search more.